Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cano, S. J.
Right arrow Articles by Warner, T. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cano, S. J.
Right arrow Articles by Warner, T. T.
Related Collections
Right arrow All Health Services Research
Right arrow Outcome research
Right arrow Dystonia
Right arrow Botulinum toxin
NEUROLOGY 2006;67:2230-2232
© 2006 American Academy of Neurology


Brief Communications

CDIP-58 can measure the impact of botulinum toxin treatment in cervical dystonia

S. J. Cano, PhD, J. C. Hobart, FRCP, M. Edwards, MRCP, R. Fitzpatrick, PhD, K. Bhatia, FRCP, A. J. Thompson, FRCP and T. T. Warner, FRCP

From the Department of Clinical Neurosciences (S.J.C., T.T.W.), Royal Free and University College Medical School, London, UK; Neurological Outcomes Measures Unit (S.J.C., J.C.H., A.J.T.), Institute of Neurology, University College London, London, UK; Department of Clinical Neurosciences (J.C.H.,), Peninsula Medical School, Plymouth, UK; Sobell Department of Motor Neuroscience and Movement Disorders (M.E., K.B.), University College London, London, UK; and Department of Public Health (R.F.), University of Oxford, Oxford, UK.

Address correspondence and reprint requests to Dr. Thomas T. Warner, Department of Clinical Neurosciences, Royal Free and University College Medical School, Rowland Hill Street, London, NW3 2PF, UK; e-mail: t.warner{at}medsch.ucl.ac.uk

We compared the responsiveness of the Cervical Dystonia Impact Profile (CDIP-58), Medical Outcome Study Short Form-Health Survey (SF-36), Functional Disability Questionnaire (FDQ), and Pain and Activities of Daily Living subscales of the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) in participants with cervical dystonia treated with botulinum toxin A. Subscales of CDIP-58 were more sensitive in detecting statistical and clinical change than comparable subscales of the SF-36, FDQ, and TWSTRS.


Supported by a project grant from the Wellcome Trust and additional support from the Dystonia Society (UK) and European Dystonia Federation. Dr. Hobart was supported in part by a grant from the NHS Health Technology Assessment Programme, but the views and opinions expressed do not necessarily reflect those of the executive.

Disclosure: The authors report no conflict of interests.

Received April 14, 2006. Accepted in final form August 30, 2006.




This article has been cited by other articles:


Home page
ptjournalHome page
B. E Crowner
Cervical Dystonia: Disease Profile and Clinical Management
Physical Therapy, November 1, 2007; 87(11): 1511 - 1526.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by AAN Enterprises, Inc.